Ocular Therapeutix (OCUL) Accumulated Expenses (2016 - 2026)
Ocular Therapeutix has reported Accumulated Expenses over the past 14 years, most recently at $36.5 million for Q1 2026.
- For Q1 2026, Accumulated Expenses rose 17.4% year-over-year to $36.5 million; the TTM value through Mar 2026 reached $36.5 million, up 17.4%, while the annual FY2025 figure was $43.8 million, 207.14% up from the prior year.
- Accumulated Expenses for Q1 2026 was $36.5 million at Ocular Therapeutix, down from $43.8 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $43.8 million in Q4 2025 and troughed at $5.4 million in Q1 2024.
- A 5-year average of $19.3 million and a median of $17.6 million in 2022 define the central range for Accumulated Expenses.
- Biggest five-year swings in Accumulated Expenses: plummeted 75.6% in 2024 and later skyrocketed 479.09% in 2025.
- Year by year, Accumulated Expenses stood at $7.5 million in 2022, then grew by 8.62% to $8.2 million in 2023, then soared by 74.99% to $14.3 million in 2024, then surged by 207.14% to $43.8 million in 2025, then decreased by 16.76% to $36.5 million in 2026.
- Business Quant data shows Accumulated Expenses for OCUL at $36.5 million in Q1 2026, $43.8 million in Q4 2025, and $13.1 million in Q3 2025.